Stock ARDS ARIDIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:51:30 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.0591 USD +0.17% Intraday chart for Aridis Pharmaceuticals, Inc. -1.99% -15.69%
2023 Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 89.88 39.66 61.1 32.75 29.39
Enterprise Value (EV) 1 65.64 18.76 53.58 20.63 30.65
P/E ratio -1.49 x -1.27 x -2.49 x -0.62 x -0.73 x
Yield - - - - -
Capitalization / Revenue 32.6 x 38.8 x 61.1 x 21.3 x 9.51 x
EV / Revenue 23.8 x 18.4 x 53.6 x 13.4 x 9.91 x
EV / EBITDA -2.75 x -0.65 x -2.43 x -0.49 x -1.05 x
EV / FCF -4.22 x -6.7 x -6.08 x -1.33 x -1.72 x
FCF Yield -23.7% -14.9% -16.5% -75.4% -58.2%
Price to Book 3.42 x 10.9 x -7.04 x -3.15 x -1.32 x
Nbr of stocks (in thousands) 8,105 8,912 10,066 14,054 24,909
Reference price 2 11.09 4.450 6.070 2.330 1.180
Announcement Date 3/28/19 4/8/20 3/30/21 4/13/22 5/22/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.86 2.757 1.022 1 1.535 3.091
EBITDA 1 -19.68 -23.83 -28.75 -22.06 -42.28 -29.28
EBIT 1 -19.74 -24.12 -29.09 -22.4 -42.71 -29.77
Operating Margin -2,295.12% -874.76% -2,846.09% -2,240.1% -2,782.48% -962.99%
Earnings before Tax (EBT) 1 -24.66 -22.1 -29.68 -22.33 -42.19 -30.37
Net income 1 -24.66 -22.1 -29.68 -22.33 -42.19 -30.37
Net margin -2,866.98% -801.78% -2,904.21% -2,233.3% -2,748.73% -982.56%
EPS 2 -165.0 -7.456 -3.509 -2.436 -3.768 -1.617
Free Cash Flow 1 -10.71 -15.55 -2.801 -8.816 -15.56 -17.85
FCF margin -1,245.73% -564.1% -274.11% -881.56% -1,013.65% -577.33%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/18/18 3/28/19 4/8/20 3/30/21 4/13/22 5/22/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales 1 0.033 0.515 0.57 1.187 0.292 0.399 1.213 - - 0.417
EBITDA - - - - - - - - - -
EBIT 1 -6.234 -21.03 -9.969 -7.424 -7.737 -7.412 -7.42 - - -0.869
Operating Margin -18,890.91% -4,082.72% -1,748.95% -625.44% -2,649.66% -1,857.64% -611.71% - - -208.39%
Earnings before Tax (EBT) 1 -5.49 -21 -10.23 -7.766 -7.979 -8.239 -10.5 - - -0.083
Net income 1 -5.49 -24.14 -13.37 -7.766 -7.979 -8.239 -10.5 - 12.14 -0.083
Net margin -16,636.36% -4,687.96% -2,345.26% -654.25% -2,732.53% -2,064.91% -865.21% - - -19.9%
EPS 2 -0.4900 -1.940 -0.9200 -0.4400 -0.4500 -0.4700 -0.5000 -0.2200 0.3300 -
Dividend per Share - - - - - - - - - -
Announcement Date 8/12/21 11/10/21 4/1/22 5/16/22 8/16/22 11/21/22 5/22/23 6/9/23 9/14/23 11/3/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - 1.25
Net Cash position 1 25.1 24.2 20.9 7.52 12.1 -
Leverage (Debt/EBITDA) - - - - - -0.0428 x
Free Cash Flow 1 -10.7 -15.6 -2.8 -8.82 -15.6 -17.8
ROE (net income / shareholders' equity) -114% -89.1% -198% 885% 387% 163%
ROA (Net income/ Total Assets) -50.3% -51.9% -61% -65% -127% -89.7%
Assets 1 48.98 42.59 48.64 34.36 33.12 33.87
Book Value Per Share 2 -377.0 3.250 0.4100 -0.8600 -0.7400 -0.9000
Cash Flow per Share 2 151.0 2.990 2.340 0.8200 1.020 0.1800
Capex 1 0.7 0.68 0.17 0.37 0.53 0.08
Capex / Sales 81.16% 24.56% 17.03% 36.7% 34.53% 2.65%
Announcement Date 7/18/18 3/28/19 4/8/20 3/30/21 4/13/22 5/22/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARIDIS PHARMACEUTICALS, INC. Stock Aridis Pharmaceuticals, Inc.
-15.69% 2.83M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 106B
BIONTECH SE Stock BioNTech SE
-10.84% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARDS Stock
  4. Financials Aridis Pharmaceuticals, Inc.